ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.

The hematology journal : the official journal of the European Haematology Association Pub Date : 2005-01-01 DOI:10.1038/sj.thj.6200570

Amel Mebazaa, Alain Dupuy, Michel Rybojad, Frédéric Mouly, Isabelle Moulonguet, Marie-Dominique Vignon-Pennamen, Jacqueline Rivet, Anne Janin, Celeste Lebbé, Louis Dubertret, Patrice Morel, Hervé Bachelez, Pauline Brice

{"title":"ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.","authors":"Amel Mebazaa, Alain Dupuy, Michel Rybojad, Frédéric Mouly, Isabelle Moulonguet, Marie-Dominique Vignon-Pennamen, Jacqueline Rivet, Anne Janin, Celeste Lebbé, Louis Dubertret, Patrice Morel, Hervé Bachelez, Pauline Brice","doi":"10.1038/sj.thj.6200570","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-cell lymphomas (CTCL) with controversial results. Our objective was to retrospectively assess efficacy and toxicity of ESHAP (etoposide, cisplatin, high-dose aracytine, methylprednisolone) in patients with advanced CTCL. A total of 11 patients with aggressive primary CTCL, treated with the ESHAP protocol between 1995 and 2002, were studied. Two patients achieved complete remissions lasting 30+ and 6+ months, seven had partial remissions of short duration, one had stable disease and one experienced disease progression. ESHAP was poorly tolerated because of prolonged myelosuppression (91%) and infectious complications (82%). Our results suggest that ESHAP has a poor risk/benefit ratio in advanced CTCL because of the low number of complete remissions, the short duration of partial remissions and its high-grade toxicity.</p>","PeriodicalId":22486,"journal":{"name":"The hematology journal : the official journal of the European Haematology Association","volume":"5 7","pages":"553-8"},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/sj.thj.6200570","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The hematology journal : the official journal of the European Haematology Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/sj.thj.6200570","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 8

Abstract

Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-cell lymphomas (CTCL) with controversial results. Our objective was to retrospectively assess efficacy and toxicity of ESHAP (etoposide, cisplatin, high-dose aracytine, methylprednisolone) in patients with advanced CTCL. A total of 11 patients with aggressive primary CTCL, treated with the ESHAP protocol between 1995 and 2002, were studied. Two patients achieved complete remissions lasting 30+ and 6+ months, seven had partial remissions of short duration, one had stable disease and one experienced disease progression. ESHAP was poorly tolerated because of prolonged myelosuppression (91%) and infectious complications (82%). Our results suggest that ESHAP has a poor risk/benefit ratio in advanced CTCL because of the low number of complete remissions, the short duration of partial remissions and its high-grade toxicity.

查看原文本刊更多论文

ESHAP治疗原发性皮肤t细胞淋巴瘤:11例患者的疗效和耐受性

全身多药血液疗法已被用于治疗侵袭性原发性皮肤t细胞淋巴瘤(CTCL)的结果有争议。我们的目的是回顾性评估ESHAP(依托泊苷、顺铂、大剂量aracytine、甲基强的松龙)治疗晚期CTCL患者的疗效和毒性。在1995年至2002年间接受ESHAP治疗的11例侵袭性原发性CTCL患者进行了研究。2例患者完全缓解持续30+月和6+月，7例患者部分缓解持续时间较短，1例病情稳定，1例病情进展。ESHAP的耐受性较差，因为长期骨髓抑制(91%)和感染性并发症(82%)。我们的研究结果表明，ESHAP在晚期CTCL中具有较差的风险/收益比，因为完全缓解的数量少，部分缓解的持续时间短，并且毒性高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The hematology journal : the official journal of the European Haematology Association

自引率

0.00%

发文量